Thursday, 15 October 2026European Markets
ExploreSearch
ViaNews EU
Source trace. Via News points to the documents behind its reporting and shows what we drew from each — so you can check any claim. How we source
Source document· April 20, 2026

Crypto News: Pepeto Presale Demand Update as Bitcoin Price Prediction Targets $250,000

View original at globenewswire.com
Crypto News: Pepeto Presale Demand Update as Bitcoin Price Prediction Targets $250,000 Dubai, UAE, April 19, 2026 (GLOBE NEWSWIRE) -- Pepeto dominates this week crypto news, where the team confirmed that presale demand hit its highest monthly pace yet with token entries growing every day as the project nears launch…
Opening lines of the source · short snapshot — read the full document at the original

What we drew from this source

The claims Via News extracted from this document. We point to the source; we don't replace it.

  • Bitcoin price will reach $250,000

    60% confidence

  • Bitcoin price base target is $150,000

    60% confidence

  • A clean break above $76,000 opens the path toward $85,000 for Bitcoin

    60% confidence

  • Total crypto market cap is expected to cross $10 trillion this year

    60% confidence

  • Bitcoin price will reach $250,000

    60% confidence

  • Presale demand hit its highest monthly pace yet with token entries growing every day

    60% confidence

  • Bitcoin price will go above $200,000

    60% confidence

  • Bitcoin will set a new all-time high this year

    60% confidence

Data points we hold from this source

Bitcoin · price75000 USD
What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Q4 2026 Biopharma Catalyst Cluster: Late-Stage Readouts and Regulatory Milestones
October 2026 brings a dense run of Phase 3 wins (ALOFT-IPF, RESTORE-3), new data presentations (Roche, Bayer, Lilly, Vertex, Galderma) and regulatory steps (FDA acceptance of Roche's vamikibart BLA, Scholar Rock's EMA resubmission). The next big catalyst is the ivonescimab FDA PDUFA date on 2026-11-14. Obesity combination studies (REDEFINE 4, TOGETHER-PsO) and the 2027 Maritime-1 completion point to more catalysts ahead. QAIAx's speculative AI-linked trial claims (the QIII pilot, targeted for 2027) are an unrelated micro-cap sideshow with weak evidence, and have little in common with the large-cap pipeline news.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,986
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,986 facts checked against source5,377 source documents archived
Query this data → isubstrate.com
Crypto News: Pepeto Presale Demand Update as Bitcoin Price Prediction Targets $250,000 — Source | Via News | ViaNews EU